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Background/aim: The purpose of this study was to assess the prevalence of anxiety and depression among patients with hirsutism and
to evaluate the relationships of anxiety and depression with clinical parameters and androgen levels.
Materials and methods: One hundred and seven women with hirsutism were enrolled in the study. All participants completed
standardized questionnaires to assess depression (Beck Depression Inventory (BDI)) and anxiety (Beck Anxiety Inventory (BAI)). The
Ferriman–Gallwey (FG) scores, body mass indexes (BMIs), homeostatic model assessments of insulin resistance (HOMA-IR), and
serum androgen levels of all patients were obtained.
Results: Seventy-four of the 107 patients (69.15%) had BDI scores indicating depression, and 47 of the 107 patients (43.9%) had BAI
scores indicating anxiety disorders. No difference was found between high BAI and normal BAI patients related to BMI, age, FG
scores, testosterone levels, and HOMA-IR levels (P > 0.05), and no difference was found between high BDI and normal BDI patients
related to BMI, age, FG scores, free testosterone levels, and HOMA-IR levels. There was a positive correlation between BDI scores and
dehydroepiandrosterone sulphate (DHEA-S) levels (P < 0.01).
Conclusion: We found considerable amounts of depression, anxiety, and the coexistence of depression and anxiety in patients with
hirsutism. Depression and the severity of depressive symptoms were positively correlated with DHEA-S levels.
Key words: Anxiety, depression, hirsutism

1. Introduction
Hirsutism is defined as the presence of excessive terminal
hair in androgen-dependent areas of a woman’s body and
affects approximately 5%–8% of the population (1,2). It
is extremely distressing for patients and has a significant
negative impact on their psychosocial development (3).
The most common causes of hirsutism are polycystic
ovary syndrome (PCOS), idiopathic hirsutism (IH), and
nonclassical congenital adrenal hyperplasia (NCAH) (4).
Other uncommon causes are ovarian tumors, adrenal
tumors, Cushing syndrome, hyperprolactinemia, thyroid
diseases, and insulin resistance (IR) syndromes.
Depression is defined as depressed mood or a loss
of interest or pleasure in daily activities for more than 2
weeks. Women suffer from depression almost twice as
often as men, and depression occurs most frequently
between the ages of 20 and 40 (5). Many researchers have
found an increased incidence of depression in women with
* Correspondence: halisecyavuz@yahoo.com

PCOS (6–8), and some researchers have even reported
a sevenfold increase in the incidence of suicide among
women with PCOS (9).
Generalized anxiety disorder (GAD) is defined as
excessive anxiety and worry about a number of events
or activities, occurring more days than not for at least 6
months, and out of proportion to the likelihood or impact
of the feared events. Anxiety disorders are also common
in PCOS (10–13). Based on a questionnaire study, Benson
et al. (10) found that 34% of 448 surveyed women with
PCOS had anxiety disorders. Anxiety-related symptoms
were associated mainly with acne and fertility problems
(10). Some studies showed that hirsutism and acne were
associated with anxiety and psychotic symptoms, whereas
other studies failed to find this association (11–13).
In the present study we aimed to evaluate the prevalence
of anxiety and depression symptoms among patients
with PCOS, congenital adrenal hyperplasia, and IH, and
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to assess whether anxiety or depression is related to the
degree of hirsutism, IR, or androgen hormone levels.
2. Materials and methods
Data were collected from 107 women with hirsutism
aged 15–49 years who were patients at the Endocrinology
outpatient clinic of Ankara Numune Research and
Training Hospital. The patients were divided into three
groups based on the diagnosis of PCOS, NCAH, or IH.
Hirsutism was assessed using Ferriman–Gallwey
scores in which the patients scored their hair growth on
nine different parts of their bodies from 0 (no terminal
hair) to 4 (maximal growth) with a maximum score of 36.
A score of 8 or more indicated the presence of hirsutism.
Patients were tested for the follicle-stimulating hormone,
the luteinizing hormone, 17-hydroxyprogesterone (17OHP), basal prolactin (PRL), total testosterone and
free testosterone, dehydroepiandrosterone sulphate
(DHEA-S), androstenedione, total cholesterol, high
density lipoprotein cholesterol, low density lipoprotein
cholesterol, and triglycerides during the follicular phase.
For all patients, blood samples and insulin were
obtained after they fasted overnight. Insulin sensitivity
was estimated using basal insulin and glucose values to
calculate the homeostatic model of IR (HOMA-IR) (14).
The diagnosis of PCOS was performed according to
the Rotterdam 2003 criteria and was given to patients with
clinical and/or biochemical hyperandrogenism, chronic
oligoanovulation, and/or polycystic ovaries on ultrasound.
Polycystic ovaries were defined as the presence of ≥12
follicles in each ovary with each follicle measuring 2–9 mm
in diameter and/or an increased ovarian volume (>10 mL).
To confirm a diagnosis of NCAH, 17-OHP concentrations
were examined in the early follicular phase. The patient
with a 17-OHP level higher than 2 ng/mL (normal: 0.2–2.6
ng/mL) was subjected to an adrenocorticotropic hormone
stimulation test (250 mcg). If the result exceeded 10 ng/
mL, a diagnosis of NCAH was confirmed.
The
diagnoses
of
thyroid
dysfunction,
hyperprolactinemia, and adrenal/ovarian tumors were
excluded. The remaining patients with normal serum
androgen concentrations and no menstrual irregularity
were diagnosed with IH.
All patients completed the Beck Depression
Inventory (BDI) and the Beck Anxiety Inventory (BAI)
questionnaires. Both the BDI and the BAI are self-report
inventories that include 21 multiple choice questions
for measuring the severity of depression and anxiety,
respectively (15,16). Scores of ≥17 on the BDI indicate
severe depression that requires treatment. Each symptom
is rated on a 4-point scale ranging from 0 (not at all)
to 4 (severely), and the total score can range from 0 to
63, with higher scores corresponding to higher levels of
anxiety/depression (16,17).
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Data analysis was performed using SPSS for Windows
11.5. Descriptive statistics were expressed as means ±
standard deviation for continuous variables and as the
number of cases (%) for categorical variables. Pearson’s chisquare or Fisher’s chi-square tests were used for categorical
variables, and P < 0.05 was considered significant. For the
normally distributed data, a t-test was used to compare the
mean values between the two groups.
3. Results
Among the 107 patients, 66 patients were diagnosed with
PCOS, 10 patients had congenital adrenal hyperplasia,
and 31 patients had IH. The demographic data for the 107
hirsute patients are given in Table 1. Patients were between
15 and 47 years of age, with BMI calculations between 16
and 37.9, and 69% of the patients had an HOMA-IR of above
2.8. Sixty-eight percent of the patients had intermediate
and high BDI scores, and 45.2% of the patients had high
BAI scores. Moreover, 43 of the 107 patients were found to
have both anxiety and depression disorders. The DHEA-S
level, the total testosterone level, and the free testosterone
level were high in 19.4%, 69.8%, and 73.5% of the patients,
respectively. The degree of depression was found to be
high in patients with a high level of DHEA-S (P < 0.01);
however, there was no correlation between DHEA-S levels
and anxiety (P = 0.18). There was no correlation between
anxiety or depression and HOMA-IR levels or BMI (Table
2). There were also no correlations between free or total
testosterone levels and depression, anxiety (P = 0.39),
or the coexistence of depression and anxiety (P = 0.46)
(Table 3). Furthermore, there was no correlation between
Table 1. Demographic and clinical data of the studied hirsute
patients.
Variables

N = 111

Age

24.06 ± 5.9

Body mass index

24.8 ± 4.8

Age at first menarche

13.43 ± 1.2

Diagnosis
Polycystic ovary syndrome

66 (61.7%)

Nonclassical congenital adrenal hyperplasia

10 (10%)

Idiopathic Hirsutism

31 (29%)

Ferriman–Gallwey score

12 (8–28)

HOMA-IR*

2.06 ± 1.4

*HOMA-IR:
resistance.

the homeostasis model assessment of insulin
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Table 2. Depression, anxiety, and correlations with clinical features of hirsute patients.

Variables

Depressed group
No (35)

Yes (72)

Ferriman–Gallwey score

Anxiety group
P-value

No (57)

Yes (47)

0.755

Depressed and anxious group
P-value

No (64)

Yes (43)

0.709

0.403

> 12

13

29

21

19

27

20

< 12

22

43

36

28

37

23

Irregular menses

0.304

0.272

0.270

Yes

16

41

28

28

33

25

No

18

30

28

18

31

17

Body mass index

0.512

0.331

0.168

< 30

30

58

49

37

55

33

> 30

5

14

8

10

9

10

HOMA–IR*

0.48

P-value

0.052

0.280

< 2.8

22

47

40

27

42

25

> 2.8

5

16

7

13

22

18

*HOMA-IR: the homeostasis model assessment of insulin resistance.
Table 3. Depression, anxiety, and correlations with androgen hormone levels.

Variables

Depressed group
No (32)

Yes (63)

DHEA-S**

Anxiety group
P-value

No (52)

Yes (43)

0.009

Depressed and anxious group
P-value

No (59)

Yes (39)

0.18

0.141

High

11

8

13

6

14

5

Normal

21

58

39

37

45

34

Androstenedione

1.000

1.000

0.633

High

28

55

44

36

49

33

Normal

3

5

4

4

6

4

Total testosterone

0.564

0.077

0.127

High

21

40

36

23

43

23

Normal

7

18

10

15

14

14

Free testosterone

0.6

P-value

0.6

High

8

19

16

11

44

30

Normal

26

48

38

33

17

10

**DHEA-S: dehydroepiandrosterone sulphate.

the severity of hirsutism and depression, anxiety, or the
coexistence of depression and anxiety.

4. Discussion
Hirsutism had a significant negative impact on healthrelated quality of life (HRQoL) measures in women and
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was associated with higher prevalence of anxiety in several
studies (13,17). Oral contraceptive treatment improved
the HRQoL measures in PCOS patients, but had no effect
on their symptoms of depression and anxiety (18). There
are a few studies showing correlations between the degree
of hirsutism and depression or anxiety. Ekbäck et al. (19)
recently found that higher levels of hair growth correlated
significantly with a lower HRQoL and with symptoms of
both anxiety and depression. In the present study, there
was no correlation between the degree of hirsutism and
depression or anxiety.
The relationship between androgen levels and mood
and behavior parameters in women is controversial.
High androgen levels may contribute to a higher risk of
psychiatric disorders in pediatric patients with genetic
causes of androgen excess. Mueller et al. (20) showed
increased rates of anxiety disorders, disruptive behavioral
disorders, and attention deficit hyperactivity disorder
in children (8–18 years) with the diagnosis of classic
congenital adrenal hyperplasia or familial male precocious
puberty. Morotti et al. (21) found that moderate hirsutism
and hyperandrogenism did not impact body image
and self-esteem as a consequence on sexual function.
However, Månsson et al. (22) found a correlation between
greater free androgen index (FAI) values and greater
levels of anxiety. In the present study, we did not find any
correlation between total testosterone or free testosterone
and depression or anxiety.
Platt et al. (23) showed that more than 50% of
adolescents diagnosed with IR and obesity reported
elevated symptoms of depression. In a cross-sectional
study, Zhao et al. (24) found that waist circumference or
abdominal obesity was significantly associated with an
increased likelihood of developing major symptoms of
depression or moderate-to-severe symptoms of depression
among overweight and obese adults in the United States. In
the present study, we did not find any association between
BMI and depression or anxiety.
The association between IR and IH is not clear.
Bonakdaran et al. (25) did not find significant differences
between the levels of serum insulin and the prevalence of
IR in PCOS, IH, and healthy subjects, but Unlühizarci et al.
(26) found an association between IR and IH. In the present
study, we did not find any association between IR and IH.

It has been shown that PCOS-diagnosed women with
high anxiety scores have significantly elevated HOMAIR and FAI values in comparison with PCOS-diagnosed
women with low anxiety scores, independently of BMI
(22). In the present study we did not find any correlation
between HOMA-IR levels and depression or anxiety.
Similarly, in other studies, there was no significant
difference between the hormonal and metabolic profiles of
PCOS patients and depression in those patients (27,28).
In our study there was a 40.1% coexistence of anxiety
and depression in hirsute patients. Benson et al. (29) and
Bazarganipour et al. (30) also showed the coexistence of
anxiety and depression in patients diagnosed with PCOS.
It has been suggested that hypothalamic-pituitaryadrenal (HPA) system dysregulation has an important
role in the pathophysiology of depression; hyperactivity
of the HPA-system in major depression is reflected by
an increased secretion of adrenal hormones, especially
cortisol and dehydroepiandrosterone (31). Morrison
et al. (32) reported that the association between serum
DHEA-S levels and symptoms of depression during the
menopausal transition varied with age. In younger women
symptoms of depression were positively associated with
DHEA-S levels, but in older women they were negatively
associated with DHEA-S levels (32). Bromberger et al.
(33) failed to find any association between DHEA-S levels
and symptoms of depression. Annagür et al. (34) found
significant association of DHEA-S levels with depression
and GAD, and significant association of 17-OHP levels
with depression. In the present study we showed positive
correlations of depression and the severity of depressive
symptoms with DHEA-S levels. In studying a group of
patients composed of young female subjects with an
average age of 24, we found that younger patients with
hirsutism and with high DHEA-S levels tended to have
more symptoms of depression.
We found considerable rates of depression, anxiety,
and comorbidity of depression and anxiety (68%, 45.2%,
and 40.1% respectively) in patients with hirsutism.
Additionally, depression and the severity of depressive
symptoms positively correlated with DHEA-S levels.
Therefore, patients with hirsutism should be screened for
accompanying depression and anxiety and more attention
should be paid to patients with high levels of DHEA-S.
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